Currently, the findings of imaging procedures used for detection or staging of prostate
cancer depend on morphology of lymph nodes or bone metabolism and do not always meet …

As described in more detail in other contributions in this issue of Seminars in Nuclear
Medicine, prostate-specific membrane antigen (PSMA) has become one of the most …

In recent years, several radioligands targeting prostate-specific membrane antigen (PSMA)
have been clinically introduced as a new class of theranostic radiopharmaceuticals for the …

Glutamate carboxypeptidase II (GCPII) is a membrane-bound binuclear zinc
metallopeptidase with the highest expression levels found in the nervous and prostatic …

Prostate cancer (PCa) is the second leading cause of cancer-related death in American
men. Positron emission tomography/computed tomography (PET/CT) with emerging …

The prostate-specific membrane antigen (PSMA) is a molecular target whose use has
resulted in some of the most productive work toward imaging and treating prostate cancer …

The high incidence rates of prostate cancer (PCa) raise demand for improved therapeutic
strategies. Prostate tumors specifically express the prostate‐specific membrane antigen …

Background Prostate-specific membrane antigen (PSMA) is a promising target for
diagnostics and therapy of prostate carcinoma (PCa). Based on the hypothesis that PSMA …

Prostate specific membrane antigen (PSMA) is a membrane-bound glutamate
carboxypeptidase overexpressed in many forms of prostate cancer. Our laboratory has …

Prostate specific membrane antigen (PSMA) otherwise known as glutamate
carboxypeptidase II (GCPII) is a membrane bound protein that is highly expressed in …